Dr Paul Cornes, MD, PhD, Consultant Oncologist, Bristol, United Kingdom

Recent Publications
- Paul Cornes P, Vulto AG, Jurczak W. Biosimilars for haematologic malignancies: the path to sustainable care. European Med Journal, 8 August 2017. https://emj.europeanmedical-group.com/wp-content/uploads/sites/2/2017/08/Biosimilars-for-Haematologic-Malignancies-The-Path-to-Sustainable-Care.pdf. Accessed March 19, 2018
- Cornes P, Muenzberg M. Biosimilars: the challenges to bring a “new” concept to market A short review of the first decade of biosimilars. Parma Horizon 2017;1(2):30-34
- Thomas Dörner, Vibeke Strand, Paul Cornes et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;0:1–9. doi:10.1136/annrheumdis-2016-209166
- Cornes P. Introducing Biosimilars to Expand Patient Access to Care. EMJ european medical journal. 2014 July:35-39. Accessed Oct 1, 2015
- Joerg Windisch, Steffen Thirstrup, Wojciech Jurczak, Paul Cornes. Biosimilars in hematology: increasing choice, expanding access. EMJ European Medical Journal - Haematology. 2014;July:30-39
Volg ons via: